(Q38769103)

6 September 2017

title

Emerging applications of metabolomics in drug discovery and precision medicine (English)

1 reference

6 September 2017

1 reference

1 reference

1

David S Wishart

1 reference

6 September 2017

publication date

11 March 2016

1 reference

Nature Reviews Drug Discovery

6 September 2017

published in

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

473-484

1 reference

Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolomics: unraveling the chemical individuality of common human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Applications of metabolomics in drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolomics: a global biochemical approach to drug response and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabonomics in humans: a new tool for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

International year of Chemistry 2011. A guide to the history of clinical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Regulation of floral scent production in petunia revealed by targeted metabolomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

High-throughput classification of yeast mutants for functional genomics using metabolic footprinting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolic fingerprinting of wild type and transgenic tobacco plants by 1H NMR and multivariate analysis technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Genomics to fluxomics and physiomics — pathway engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Global analyses of cellular lipidomes directly from crude extracts of biological samples by ESI mass spectrometry: a bridge to lipidomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Advances in metabolite identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Quantitative metabolomics using NMR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Modern analytical techniques in metabolomics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Measuring the metabolome: current analytical technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The human serum metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The human urine metabolome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

LC-MS/MS progress in newborn screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Bayesian deconvolution and quantification of metabolites in complex 1D NMR spectra using BATMAN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Accurate, fully-automated NMR spectral profiling for metabolomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metab: an R package for high-throughput analysis of metabolomics data generated by GC-MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

ADAP-GC 2.0: deconvolution of coeluting metabolites from GC/TOF-MS data for metabolomics studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Imaging mass spectrometry: from tissue sections to cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolic imaging of mild traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: metabolite quantification at 4T vs. 7T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

C-11 radiochemistry in cancer imaging applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Intraoperative tissue identification using rapid evaporative ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Gold nanoparticle-enhanced target (AuNPET) as universal solution for laser desorption/ionization mass spectrometry analysis and imaging of low molecular weight compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

MALDI imaging mass spectrometry: spatial molecular analysis to enable a new age of discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Progress and promise of genome-wide association studies for human complex trait genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Personal genomes: The case of the missing heritability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Drug discovery in jeopardy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

How many drug targets are there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Actual Causes of Death in the United States, 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The food metabolome: a window over dietary exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Determining microbial products and identifying molecular targets in the human microbiome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Genetics of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Transmission of atherosclerosis susceptibility with gut microbial transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Cancer as a metabolic disease: implications for novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Oncometabolites: linking altered metabolism with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Is Cancer a Genetic Disease or a Metabolic Disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The oncometabolite fumarate promotes pseudohypoxia through noncanonical activation of NF-κB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Diet, lifestyle, and the risk of type 2 diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolite profiles and the risk of developing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

2-Aminoadipic acid is a biomarker for diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The role of microbial amino acid metabolism in host metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Chronic leucine supplementation increases body weight and insulin sensitivity in rats on high-fat diet likely by promoting insulin signaling in insulin-target tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

HMDB 3.0--The Human Metabolome Database in 2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an abnormal phenylalanine metabolite of Clostridia spp. in the gastrointestinal tract, in urine samples from patients with autism and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Plasma phospholipids identify antecedent memory impairment in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Microbiota metabolite regulation of host immune homeostasis: a mechanistic missing link

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Principles of early drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Cancer's molecular sweet tooth and the Warburg effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Alzheimer's disease is type 3 diabetes-evidence reviewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Targeting enzyme inhibitors in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Medical foods: products for the management of chronic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The historical evolution of thought regarding multiple micronutrient nutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The ketogenic diet: uses in epilepsy and other neurologic illnesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabonomics: a platform for studying drug toxicity and gene function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabonomics in pharmaceutical R&D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

LC-MS-based metabolomics in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Fast and highly selective LC-MS/MS screening for THC and 16 other abused drugs and metabolites in human hair to monitor patients for drug abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Urine specimen detection of concurrent nonprescribed medicinal and illicit drug use in patients prescribed buprenorphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Untargeted metabolomics as a screening tool for estimating compliance to a dietary pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

A novel approach to quantitative LC-MS/MS: therapeutic drug monitoring of clozapine and norclozapine using isotopic internal calibration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolic phenotyping applied to pre-clinical and clinical studies of acetaminophen metabolism and hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Quantification and validation of HPLC-UV and LC-MS assays for therapeutic drug monitoring of ertapenem in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Personal omics profiling reveals dynamic molecular and medical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

P4 medicine: how systems medicine will transform the healthcare sector and society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Integrating big data and actionable health coaching to optimize wellness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Translational biomarker discovery in clinical metabolomics: an introductory tutorial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Mass spectrometry in clinical chemistry: the case of newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

An empirical assessment of validation practices for molecular classifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

From the lab to the prescription pad: genetics, CYP450 analysis, and medication response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The limits of genome-wide methods for pharmacogenomic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

LC-MS/MS for immunosuppressant therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Liquid chromatography-tandem mass spectrometry method for simultaneous determination of cyclosporine A and its three metabolites AM1, AM9 and AM4N in whole blood and isolated lymphocytes in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method: application to pharmacokinetic study in healthy volunteers and renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Liquid chromatography-tandem mass spectrometry outperforms fluorescence polarization immunoassay in monitoring everolimus therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabolomics of statin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Human metabolic individuality in biomedical and pharmaceutical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

An atlas of genetic influences on human blood metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Pharmacometabolomics reveals racial differences in response to atenolol treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Molecular tumor profiling for prediction of response to anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using ¹⁸F-FDG-PET and MRSI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Targeting glutamine metabolism in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

MetaboLights--an open-access general-purpose repository for metabolomics studies and associated meta-data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Proposed minimum reporting standards for chemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

MetaboAnalyst 3.0--making metabolomics more meaningful

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The emerging role of fumarate as an oncometabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Oncometabolites-driven tumorigenesis: From genetics to targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The role of sarcosine metabolism in prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Glutamine addiction: a new therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

c-Myc and cancer metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The role of choline in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metabolism and its sequelae in cancer evolution and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

A Short History of Nutritional Science: Part 3 (1912–1944)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

An untargeted metabolomics approach to contaminant analysis: Pinpointing potential unknown compounds

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Metallomics: a new frontier in analytical chemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The blood exposome and its role in discovering causes of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

The human microbiome: at the interface of health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Epigenetics and the environment: emerging patterns and implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

Validation of incorporating flurbiprofen into the Pittsburgh cocktail

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.32

LC-MS/MS in the Clinical Laboratory - Where to From Here?

31 March 2020

1 reference

12 December 2020

AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role

1 reference

12 December 2020

The biosynthesis of trimethylamine-N-oxide

1 reference

12 December 2020

Simultaneous online SPE-HPLC-MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.32

1 reference

6 September 2017

1 reference